5YQO
Crystal structure of Sirt2 in complex with selective inhibitor L5C
5YQO の概要
エントリーDOI | 10.2210/pdb5yqo/pdb |
分子名称 | NAD-dependent protein deacetylase sirtuin-2, ZINC ION, N-[4-[[3-[2-(4,6-dimethylpyrimidin-2-yl)sulfanylethanoylamino]phenyl]methoxy]phenyl]-1-methyl-pyrazole-4-carboxamide, ... (4 entities in total) |
機能のキーワード | nad-dependent deacetylase sirtuin-2, inhibitor, complex, hydrolase-hydrolase inhibitor complex, hydrolase/hydrolase inhibitor |
由来する生物種 | Homo sapiens (Human) |
タンパク質・核酸の鎖数 | 1 |
化学式量合計 | 35017.67 |
構造登録者 | |
主引用文献 | Yang, L.L.,Wang, H.L.,Zhong, L.,Yuan, C.,Liu, S.Y.,Yu, Z.J.,Liu, S.,Yan, Y.H.,Wu, C.,Wang, Y.,Wang, Z.,Yu, Y.,Chen, Q.,Li, G.B. X-ray crystal structure guided discovery of new selective, substrate-mimicking sirtuin 2 inhibitors that exhibit activities against non-small cell lung cancer cells. Eur J Med Chem, 155:806-823, 2018 Cited by PubMed Abstract: Human sirtuin 2 (SIRT2) is a nicotinamide adenine dinucleotide (NAD)-dependent deacylase, and is implicated in human diseases including cancer. Selective small-molecule inhibitors for SIRT2 are sought as chemical tools and potential therapeutics. Here we report the X-ray crystal structure guided structure-activity relationship studies of new N-(3-(phenoxymethyl)phenyl)acetamide derivatives with SIRT2, which led to the identification of potent, selective SIRT2 inhibitors. Crystallographic analyses reveal that the new inhibitors act via inducing the formation of an enlarged hydrophobic pocket and particularly mimicking the interactions made by myristoylated-lysine substrates. The most potent inhibitor 24a could dose-dependently elevate the acetylation level of α-tubulin in the non-small cell lung cancer H441 cells, which have a high expression level of SIRT2 as determinated by Western blotting analyses. Further cellular assays reveal that 24a restrains cell growth mainly through inhibiting cellular proliferation rather than inducing apoptosis. Moreover, 24a could suppress the migration and invasion of H441 cells. These results provide an excellent basis for further development of new potent, selective, and cell active SIRT2 inhibitors as chemical tools and potential therapeutics for SIRT2-driven non-small cell lung cancers. PubMed: 29957526DOI: 10.1016/j.ejmech.2018.06.041 主引用文献が同じPDBエントリー |
実験手法 | X-RAY DIFFRACTION (1.483 Å) |
構造検証レポート
検証レポート(詳細版)をダウンロード